Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
- Broad-spectrum beta-lactam/beta-lactamase inhibitor combination (ureidopenicillin + beta-lactamase inhibitor). Active against many gram-negative, gram-positive, and anaerobic bacteria, including Pseudomonas aeruginosa and ESBL-producing organisms (though susceptibility varies locally).
## Primary Indications
- Hospital-acquired pneumonia (including ventilator-associated)
- Intra-abdominal infections (complicated)
- Urinary tract infections (complicated, pyelonephritis)
- Skin and soft tissue infections (complicated)
- Febrile neutropenia (in combination with other agents per local protocol)
- Empiric treatment for moderate-to-severe infections in hospitalized patients
## Adult Dosing
- **Normal renal function (CrCl ≥20 mL/min):**
- Standard: 3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours
- Extended infusion preferred for critically ill: 3.375 g IV over 4 hours every 8 hours, or 4.5 g IV over 4 hours every 8 hours (local protocol dependent)
- **Severe infections/Pseudomonas:** Extended infusion often recommended.
- Maximum daily dose: 18 g piperacillin component (4.5 g q6h) or 13.5 g (3.375 g q8h extended infusion) – but always verify local guidelines.
## Pediatric Dosing (≥2 months)
- **General dosing:** 80 mg/kg/dose (based on piperacillin component) IV every 6 hours (typical maximum 4 g/dose piperacillin).
- **Neonates (<2 months):** Postnatal age/weight-based per local protocol; consult specialist.
- **Maximum daily dose:** 18 g piperacillin component (or as per local guidelines).
## Dose Adjustments
- **Renal impairment (adults):**
- CrCl 20–40 mL/min: 3.375 g IV every 8 hours
- CrCl <20 mL/min: 3.375 g IV every 12 hours
- Hemodialysis: 3.375 g IV every 12 hours (give after dialysis on dialysis days)
- **Pediatric renal adjustments:** Use established nomograms; consult pharmacy.
- **No hepatic adjustment needed.**
## Contraindications
- Hypersensitivity to penicillins, cephalosporins, or beta-lactamase inhibitors (cross-reactivity possible).
- Known anaphylactic reaction to beta-lactam agents.
## Adverse Effects
- **Common:** Diarrhea, nausea, rash, phlebitis at IV site.
- **Serious:** Clostridioides difficile infection, anaphylaxis, acute interstitial nephritis, hematologic toxicity (neutropenia, thrombocytopenia especially with prolonged use >10–14 days), neurotoxicity (seizures with high doses/renal failure).
## Key Drug Interactions
- **Methotrexate:** Piperacillin may reduce MTX clearance → increased toxicity.
- **Warfarin:** Enhanced anticoagulation (monitor INR).
- **Aminoglycosides:** In vitro synergism shown; but physical incompatibility in IV line (do not mix in same bag).
- **Probenecid:** Reduces tubular secretion of piperacillin (increases levels – use with caution).
## Monitoring
- Renal function (creatinine, CrCl) at baseline and daily.
- CBC with differential if therapy >7–10 days (monitor for neutropenia/thrombocytopenia).
- Signs of hypersensitivity, superinfection, or C. difficile diarrhea.
- Therapeutic drug monitoring not routinely required for piperacillin/tazobactam.
## Clinical Pearls
- Extended infusion (e.g., over 4 hours) optimizes pharmacodynamic target (time above MIC) for Pseudomonas and severe infections.
- Do NOT mix with aminoglycosides in same IV line due to physical incompatibility; administer separately or use Y-site compatible fluids.
- Often considered carbapenem-sparing alternative for ESBL infections if MICs are low (local antibiogram must guide).
- High sodium content: approximately 2.84 mEq sodium per gram of piperacillin; consider in fluid-overloaded patients.
- Dose reduction in renal impairment is essential to avoid neurotoxicity.
*Disclaimer: This information is a summary for educational purposes. Always verify current prescribing information, local resistance patterns, and institutional protocols before prescribing. Dosing adjustments depend on individual patient factors and formulary guidelines.*
